Corteva Growth Improves, But Valuation Limits Upside

Corteva delivered a solid first half of 2026, with net sales increasing 4% year over year to $11.28 billion and operating EBITDA rising 10% to $3.70 billion. Operating EPS increased 14% to $3.80. Management raised its full-year outlook and now expects operating EBITDA of $4.1-$4.3 billion and operating EPS of $3.60-$3.80 per share.

Growth Drivers Remain in Place

The Seed segment continues to be the primary growth contributor. First-half Seed net sales increased 4% to $7.56 billion, helped by higher price/mix, demand for differentiated germplasm and trait technologies and improved royalty economics. Segment operating EBITDA increased 11% to $3 billion, supported by pricing actions and lower royalty expense.

Corteva’s Crop Protection business is also benefiting from new product adoption. In the first half of 2026, Crop Protection sales increased 3%, with volume growth from new products helping offset a 3% pricing decline caused by competitive conditions, particularly in Latin America.

Productivity initiatives remain another earnings driver. Management cited more than $160 million in cost improvements from lower input costs, manufacturing efficiencies and productivity programs during the first half of 2026.

Separation Adds a Near-Term Execution Risk

Corteva is preparing to separate its businesses into two standalone public companies, targeting completion on Oct. 1, 2026. Management has reported that run-rate dis-synergies are largely offset, but remaining steps include final capital structures, Form 10 effectiveness and IT separation activities.

The transition could require additional management focus as Corteva prepares both businesses to operate independently. The company included a $25 million headwind in 2026 guidance related to separation timing.

Valuation Leaves Less Room for Error

Corteva’s valuation reflects some of the expected earnings improvement. The stock trades at 19.6X forward 12-month earnings, with a PEG ratio of 2.2X. Its Zacks Style Scores include a Value Score of D, Growth Score of F, Momentum Score of C and VGM Score of F.

Image Source: Zacks Investment Research

While earnings growth expectations have improved, valuation remains a concern if Crop Protection pricing pressure persists or separation-related costs weigh on results.

Corteva competes within the broader agricultural sector alongside companies such as Archer Daniels Midland Company ADM and Adecoagro S.A. AGRO. Corteva focuses primarily on agricultural technology solutions, including seeds and crop protection products, while ADM operates a large-scale agricultural processing and commodities platform and AGRO has exposure to farming, sugar, ethanol and agricultural production assets.

Bottom Line

Corteva’s improving fundamentals are supported by Seed technology demand, new Crop Protection products and cost discipline. The company has raised its 2026 outlook and continues to execute on its separation plan. However, elevated valuation, competitive pricing pressure and execution risks around the separation limit near-term upside potential.

Given the balance between improving earnings trends and valuation concerns, CTVA appears more suitable for investors seeking exposure to agricultural technology growth but willing to accept moderate near-term upside potential.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research